Zhengming Yang

Tongji Hospital, Wu-han-shih, Hubei, China

Are you Zhengming Yang?

Claim your profile

Publications (4)5.09 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Activated epidermal growth factor receptor (EGFR) has emerged as an important therapeutic target for a variety of solid tumors, particularly malignant gliomas. A recently discovered transmembrane glycoprotein, LRIG1, antagonizes the activity of epidermal growth factor receptor family receptor tyrosine kinases and acts as a negative feedback loop of EGFR and proposed tumor suppressors. The aim of this study was to investigate the impact of LRIG1 on the biological features of glioma cells and the possible mechanisms of enhanced apoptosis induced by upregulation of LRIG1. We observed that the expression of LRIG1 was decreased, while the expression of EGFR was increased in the majority of astrocytomas, and the ratio of EGFR/LRIG1 was increased by sixfold in tumors versus corresponding non-neoplastic tissue. Upregulation of LRIG1, followed by a decrease of EGFR on the cytomembrane of the cells, induced cell apoptosis and cell growth inhibition, and further reversed invasion in glioma cell lines and primary glioma cells. Our study now clearly indicates that LRIG1 indeed affects cell fate and biology behaviors of the cells in vitro by inhibiting phosphorylation of downstream MAPK and AKT signaling pathway, and the elevated release level of caspase-8 might contribute to the enhanced apoptosis in LRIG1 transfected glioma cells. Taken together, these findings provide us with an insight into LRIG1 function, and we conclude that LRIG1 evolved in gliomas as a rare feedback negative attenuator of EGFR and could offer a novel therapeutic target to treat patients with malignant gliomas.
    Journal of Neuro-Oncology 04/2009; 94(2):183-94. · 3.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors performed a study to investigate the clinical manifestations, treatment strategies, and possible pathogenesis of conus medullaris schistosomiasis. Six cases collected from the authors' experience and four cases reported in the literature were studied retrospectively for clinical manifestations, treatment outcomes, and prognosis. All patients experienced progressive lower-extremity weakness and functional bowel and bladder impairment. Although the magnetic resonance (MR) imaging results suggested the presence of a conus medullaris tumor, schistosomiasis was diagnosed based on pathological results obtained in the 10 patients. The results of surgery followed by pyquiton and hormone treatment confirmed the diagnosis, and the patients' prognoses were good. This pathological entity is predominantly found in adults, and the clinical manifestations have no specificity, although the MR imaging may provide some clues. As a form of ectopic schistosomiasis, conus medullaris schistosomiasis deserves special consideration and further exploration. If an early diagnosis can be made and pyquiton and hormone therapy is given, surgery can be avoided and the prognosis will remain good.
    Journal of Neurosurgery Spine 09/2006; 5(2):146-9. · 1.98 Impact Factor
  • Zhengming YANG, Mingsheng WANG, Jian CHEN
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To investigate the inhibitory effects of combination chemotherapy of Carboplatin (CBP), Teniposide (Vm-26), Methasquin (MTX), and Nimodipine (NIM) on glioma, and to explore the sensitivity of glioma cells to different treatment regimens so as to provide some clues for clinical usage of interstitial combination chemotherapy. Methods: MTT assay and 3H-TdR incorporation assay were performed to evaluate the inhibitory effects upon the proliferation of glioma cells, and to compare the sensitivity of glioma cells to administration of CBP, Vm-26, MTX, and NIM with that of the administration of CBP+NIM, Vm-26+NIM, MTX+NIM, CBP+Vm-26+MTX, or CBP+Vm-26+MTX+NIM, respectively. Results: The inhibition rate of CBP+Vm-26+MTX+NIM combination administration against glioma cells was 96.64%, higher than that of CBP+NIM (69.03%), Vm-26+NIM (71.53%), MTX+NIM (52.75%), CBP+Vm-26+MTX (78.59%) (P<0.01), and the dosage of CBP, Vm-26, and MTX was declined to 1/10- 1/100 that of respective use of CBP, Vm-26, and MTX. Conclusion: The curative effect of combination administration of CBP, Vm-26, MTX, and NIM was much better than that of respective administration, suggesting a higher inhibition rate and a lower dosage use.
    The Chinese-German Journal of Clinical Oncology 11/2005; 4(6):378-380.
  • [Show abstract] [Hide abstract]
    ABSTRACT: ObjectiveTo determine the method and significance of facial nerve preservation during acoustic neurinoma surgery by intra-operative facial nerve monitoring (IFNM). Methods62 patients were randomly assigned to the IFNM or the control group. Facial nerve function (FNF) was assessed by a modified House-Brackmann grading (HB) before the operation, 10 days and every two months after surgery and compared between the two groups. ResultsTen days after surgery, 26/32 patients in the IFNM group and 15/30 patients in the control group had FNF HB grade I–III; FNF HB grade IV–V was present in 6/32 in the IFNM group and 15/30 in the control group. During follow-up, 29/32 patients in the IFNM group and 20/30 patients in the control group had FNF HB grade I–III; FNF HB grade IV–V was present in 3/32 in the IFNM group and 10/30 in the control group. All differences were statistically significant. ConclusionIFNM significantly improved anatomic and functional facial nerve preservation as well as the quality of life.
    The Chinese-German Journal of Clinical Oncology 1(3):168-169.